SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Commission File Number: 001-40582
NOTIFICATION OF LATE FILING
|☐ Form 10-K||☐ Form 20-F||☐ Form 11-K||☒ Form 10-Q|
|☐ Form 10-D||☐ Form N-SAR||☐ Form N-CSR|
For Period Ended: March 31, 2023
|☐ Transition Report on Form 10-K||☐ Transition Report on Form 10-Q|
|☐ Transition Report on Form 20-F||☐ Transition Report on Form N-SAR|
|☐ Transition Report on Form 11-K|
For the Transition Period Ended: _______________________________________
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________
|Full name of registrant||Unicycive Therapeutics, Inc.|
|Former name if applicable|
|Address of principal executive office||4300 El Camino Real, Suite 210|
|City, state and zip code||Los Altos, CA 94022|
RULE 12b-25 (b) AND (c)
If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)
|(a)||The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;|
|☒||(b)||The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and|
|(c)||The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.|
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within the prescribed time period.
The Company is unable to file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 within the prescribed time period because additional time is required to finalize its financial statements to be filed as part of the Form 10-Q. The Company expects to file the Form 10-Q within the extension period of 5 calendar days.
(1) Name and telephone number of person to contact in regard to this notification
|(Name)||(Area Code)||(Telephone Number)|
(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
☒ Yes ☐ No
(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
☒ Yes ☐ No
If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
For the three months ended March 31, 2023, total other income (expenses) and net loss increased to $(10.1 million) and $(14.4 million) from 0 and $(3.5 million) for the three months ended March 31, 2022, respectively. The increased expense is primarily the result of a change in fair value of warrant liability.
Unicycive Therapeutics, Inc.
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
|Dated: May 16, 2023||/s/ John Townsend|
|Title:||Chief Financial Officer|